pharma news
Mar 31, 2022
Ypsomed-CamDiab’s Collaboration; Vela Diagnostics’s NGS-Based Pan-Cancer Panels; Fresenius’s SMOFlipid Lipid Injectable Emulsion; Sientra Gained Regulatory Nod to Market Breast Implants; Synchron’s Endovascular BCI Stentrode Device; HLT’s TAVR Clinical Studies
Ypsomed Collaborated with CamDiab for Smartphone-based Automated Insulin Delivery On March 22, 2022, Ypsomed, a leading manufacturer of injection and infusion systems for self-medication partnered with CamDiab Ltd, developer of CamAPS FX, an app for the management of glucose levels via insulin pumps using an ada...
Read More...
Mar 22, 2022
Bristol Myers’ Opdivo combo Opdualag for Melanoma; Biogen’s Aduhelm; Marinus’ Ztalmy for CDKL-5 Deficiency Disorder; Merck’s Keytruda + Lynparza; Vitaris’s Breyna; Moderna’s Second COVID-19 Booster Shot; Takeda’s Exkivity; BMS’s First LAG-3 Checkpoint Inhibitor
NHS Grants Fast Track Access to Takeda’s Exkivity Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks. The Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorisa...
Read More...
Mar 15, 2022
AstraZeneca and Merck’s Lynparza; Venatorx’s cefepime-taniborbactam; AbbVie’s Qulipta; AstraZeneca’s IL-5 inhibitor Fasenra; Sandoz Acquires Coalesce; Incyte’s Opxelura; Bayer’s Nubeqa; NICE Rejects Keytruda Plus Chemotherapy
FDA Clears AstraZeneca and Merck’s Lynparza as an Adjuvant Breast Cancer Therapy The FDA approved the AstraZeneca and Merck drug for a specific group of patients with high-risk early breast cancer after chemotherapy treatment, either before or after surgery. Lynparza cements its position as the best-selling PARP...
Read More...
Mar 08, 2022
Lilly & Boehringer’s Jardiance; BMS Secures a Neoadjuvant Market for Opdivo; Amgen & NHS Signs a Deal; Roche’s Alzheimer Drug gantenerumab; Pfizer’s RSV Vaccine; Civica’s Insulin Biosimilars; Eli Lilly & Incyte’s JAK inhibitor Olumiant; Natco Pharma Launches Revlimid Generic
Eli Lilly, Boehringer Ingelheim’s Jardiance Giving Competition to AstraZeneca’s Farxiga with EU Approval Jardiance, the diabetes blockbuster from Eli Lilly and Boehringer Ingelheim, recently received a Heart Failure label expansion in the United States. Now, the drug is expanding into Europe, with a nod that mig...
Read More...
Mar 01, 2022
GSK’s Covifenz; Idorsia’s Quviviq; GSK’s ZEJULA; EMA Expands its Nod for BMS, Eli Lilly, and Novartis Drugs; Cantex Secures Global Licence to Develop Azeliragon; Biocon Acquires Viatris’ Biosimilar Business
GSK’s Covifenz, A Plant-Based COVID Vaccine, Receives First Approval The recombinant COVID-19 vaccine developed by Medicago, now known as Covifenz, has received approval in Canada, the company's home country. Covifenz employs Coronavirus-Like Particle (CoVLP) technology, with the vaccine consisting of recombinan...
Read More...
Feb 22, 2022
Sandoz’s Generic Revlimid; Agios’ Pyrukynd; Organon Announces 4Q & Full-year Earnings Report; BMS’ CAR-T Drug Breyanzi; Sanofi & Regeneron’s Dupixent Trial; AZ & Daiichi’s Drug Enhertu; Bayer’s Drug Kerendia; Lilly Releases Mirikizumab Data
Sandoz Launches generic Revlimid in 19 European Countries, Bringing a Flood of Competition to BMS' Megablockbuster Since Bristol Myers Squibb acquired Celgene and its megablockbuster Revlimid, the company has been bracing for the day when the multiple myeloma superstar would face generic competition. Sandoz, a s...
Read More...
Feb 08, 2022
Biogen’s Aduhelm; FDA Approves Sanofi’s Enjaymo; NHS & Orchard Signs a Deal; Bristol’s Breyanzi & Abecma; Pharming’s Leniolisib; Eli Lilly’s Verzenio Trial; UCB’ Zilucoplan Trials Result; Eli Lilly’s Alzheimer’s Drug Donanemab
Biogen's Aduhelm Marketing and Approval are Under Scrutiny in New FTC and SEC Investigations Biogen can't seem to get a break when it comes to the Alzheimer's disease drug Aduhelm. Along with limited sales and a constraining Medicare coverage plan, the medicine is now facing additional scrutiny as part of a pair...
Read More...
Feb 01, 2022
Immunocore’s Kimmtrak; Samsung Acquires Biogen’s Biosimilar Unit; Novavax’s COVID-19 Vaccine; CHMP Approves Dupixent (dupilumab); Glenmark’s High Blood Pressure Treatment; Roche’s Faricimab; GBT’s Voxelotor
Immunocore Receives FDA Approval for the First Uveal Melanoma Treatment, As Well As the First T-cell Receptor Therapeutics Uveal Melanoma, an aggressive eye cancer, has proven to be a tough nut to crack for researchers seeking a cure. However, with the approval of a new treatment, those with the disorder will ha...
Read More...
Jan 25, 2022
Merck’s Gefapixant; Pfizer’s Somatrogon; Gilead’s Viklury; AbbVie’s Skyrizi; Gilead’s Zydelig Approvals; Lantern’s LP-184; Polpharma to Acquire Advent
Merck’s Chronic Cough Med Gefapixant Receives A Red Flag From the FDA, Requests For More Data On 24th January 2022, Merck & Co. announced FDA rejection for its New Drug Application (NDA) of Gefapixant (experimental drug) for unexplained or chronic cough. FDA asked for additional information on the drug, rela...
Read More...
Jan 18, 2022
Algernon’s NP-120 (ifenprodil); Pieris’s cinrebafusp alfa (PRS-343) clinical trial; Gaumard Scientific’s multidisciplinary patient simulator HAL S5301; Hekka Labs’s decentralized healthcare ecosystem
Algernon receives positive FDA feedback on Phase IIb chronic cough trial The US Food and Drug Administration (FDA) has given positive feedback for Algernon Pharmaceuticals’ Phase IIb clinical trial of NP-120 (ifenprodil) for chronic cough treatment. A receptor antagonist of N-methyl-D-aspartate (NMDA), ifenp...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
